249 related articles for article (PubMed ID: 21531450)
1. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN; McLaughlin PJ; Zagon IS
Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
[TBL] [Abstract][Full Text] [Related]
2. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
Zagon IS; Donahue R; McLaughlin PJ
Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
[TBL] [Abstract][Full Text] [Related]
3. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
[TBL] [Abstract][Full Text] [Related]
4. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
5. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
[TBL] [Abstract][Full Text] [Related]
6. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
Rahn KA; McLaughlin PJ; Zagon IS
Brain Res; 2011 Mar; 1381():243-53. PubMed ID: 21256121
[TBL] [Abstract][Full Text] [Related]
7. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891
[TBL] [Abstract][Full Text] [Related]
8. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
[TBL] [Abstract][Full Text] [Related]
9. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
Zagon IS; McLaughlin PJ
Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893
[TBL] [Abstract][Full Text] [Related]
10. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
[TBL] [Abstract][Full Text] [Related]
11. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
Zagon IS; Ruth TB; McLaughlin PJ
Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
[TBL] [Abstract][Full Text] [Related]
12. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
Zagon IS; McLaughlin PJ
Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
[TBL] [Abstract][Full Text] [Related]
14. Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer.
Fanning J; Hossler CA; Kesterson JP; Donahue RN; McLaughlin PJ; Zagon IS
Gynecol Oncol; 2012 Feb; 124(2):319-24. PubMed ID: 22037317
[TBL] [Abstract][Full Text] [Related]
15. Reepithelialization of the human cornea is regulated by endogenous opioids.
Zagon IS; Sassani JW; McLaughlin PJ
Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604
[TBL] [Abstract][Full Text] [Related]
16. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
Immonen JA; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
[TBL] [Abstract][Full Text] [Related]
17. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2012 Feb; 237(2):167-77. PubMed ID: 22328595
[TBL] [Abstract][Full Text] [Related]
18. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
19. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor.
McLaughlin PJ; Zagon IS
Int J Oncol; 2006 Jun; 28(6):1577-83. PubMed ID: 16685459
[TBL] [Abstract][Full Text] [Related]
20. Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery.
Zagon IS; Essis FM; Verderame MF; Healy DA; Atnip RG; McLaughlin PJ
J Vasc Surg; 2003 Mar; 37(3):636-43. PubMed ID: 12618704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]